Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Current and future targets of antiviral therapy in the hepatitis C virus life cycle
Author: Eyre, N.
Helbig, K.
Beard, M.
Citation: Future Virology, 2014; 9(11):947-965
Publisher: Future Medicine
Issue Date: 2014
ISSN: 1746-0794
Statement of
Nicholas S Eyre, Karla J Helbig and Michael R Beard
Abstract: Advances in our understanding of the hepatitis C virus (HCV) life cycle have enabled the development of numerous clinically advanced direct-acting antivirals. Indeed, the recent approval of first-generation direct-acting antivirals that target the viral NS3–4A protease and NS5B RNA-dependent RNA polymerase brings closer the possibility of universally efficacious and well-tolerated antiviral therapies for this insidious infection. However, the complexities of comorbidities, unforeseen side effects or drug–drug interactions, viral diversity, the high mutation rate of HCV RNA replication and the elegant and constantly evolving mechanisms employed by HCV to evade host and therapeutically implemented antiviral strategies remain as significant obstacles to this goal. Here, we review advances in our understanding of the HCV life cycle and associated opportunities for antiviral therapy.
Keywords: antiviral; assembly; egress; entry; HCV; IFN; NS3-4A; NS5A; NS5B; replication
Description: Review
Rights: © 2014 Future Medicine Ltd.
DOI: 10.2217/FVL.14.83
Appears in Collections:Aurora harvest 3
Molecular and Biomedical Science publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.